Clinical Trial Update: Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa [Phase 3]

View source ↗

Summary

Phase 3 extension study evaluating non-interrupted vs interrupted and two dosing regimens of secukinumab in hidradenitis suppurativa; results were posted in 202…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hidradenitis Suppurativa | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-06-21